

Gonococcal Isolate Surveillance Project (GISP) Table California, 2019

- Isolates by Type of Resistance, California Sites, 2015–2019

Gonococcal Isolate Surveillance Project (GISP), Isolates by Type of Resistance, California Sites, 2015–2019

CLINIC SITE	2015 Number	2015 Percent	2016 Number	2016 Percent	2017 Number	2017 Percent	2018 Number	2018 Percent	2019 Number	2019 Percent
TOTALS										
Total Specimens	816		868		867		716		608	
No Resistance	358	43.9	387	44.6	338	39.0	258	36.0	195	32.1
Ceftriaxone Decreased Susceptibility ¹	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Cefixime Decreased Susceptibility ²	0	0.0	1	0.1	0	0.0	0	0.0	0	0.0
Azithromycin Decreased Susceptibility ³	9	1.1	32	3.7	29	3.3	58	8.1	60	9.9
Ciprofloxacin Decreased Susceptibility ⁴	16	2.0	7	0.8	10	1.2	7	1.0	21	3.5
Ciprofloxacin-Resistant ⁵	246	30.1	313	36.1	392	45.2	332	46.4	316	52.0
Other Drug Resistance*	369	45.2	337	38.8	311	35.9	252	35.2	217	35.7
Los Angeles (LA)										
Total Specimens	81		133		199		160		157	
No Resistance	43	53.1	51	38.3	78	39.2	41	25.6	48	30.6
Ceftriaxone Decreased Susceptibility	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Cefixime Decreased Susceptibility	0	0.0	1	0.8	0	0.0	0	0.0	0	0.0
Azithromycin Decreased Susceptibility	3	3.7	6	4.5	8	4.0	10	6.3	15	9.6
Ciprofloxacin Decreased Susceptibility	0	0.0	1	0.8	3	1.5	2	1.3	9	5.7
Ciprofloxacin-Resistant	18	22.2	59	44.4	85	42.7	82	51.3	82	52.2
Other Drug Resistance*	34	42.0	53	39.8	73	36.7	62	38.8	57	36.3
Orange										
Total Specimens	182		194		142		164		159	
No Resistance	86	47.3	79	40.7	62	43.7	70	42.7	60	37.7
Ceftriaxone Decreased Susceptibility	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Cefixime Decreased Susceptibility	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Azithromycin Decreased Susceptibility	0	0.0	5	2.6	3	2.1	9	5.5	8	5.0
Ciprofloxacin Decreased Susceptibility	1	0.5	2	1.0	0	0.0	0	0.0	6	3.8
Ciprofloxacin-Resistant	53	29.1	74	38.1	62	43.7	76	46.3	85	53.5
Other Drug Resistance*	74	40.7	82	42.3	54	38.0	54	32.9	50	31.4
San Diego (SD)										
Total Specimens	189		195		195		150		133	
No Resistance	69	36.5	81	41.5	67	34.4	52	34.7	29	21.8

CLINIC SITE	2015	2015	2016	2016	2017	2017	2018	2018	2019	2019
	Number	Percent	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Ceftriaxone Decreased Susceptibility	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Cefixime Decreased Susceptibility	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Azithromycin Decreased Susceptibility	1	0.5	3	1.5	2	1.0	11	7.3	11	8.3
Ciprofloxacin Decreased Susceptibility	2	1.1	2	1.0	3	1.5	3	2.0	4	3.0
Ciprofloxacin-Resistant	59	31.2	78	40.0	109	55.9	73	48.7	79	59.4
Other Drug Resistance*	102	54.0	91	46.7	63	32.3	50	33.3	51	38.3
San Francisco (SF)										
Total Specimens	364		346		331		242		159	
No Resistance	160	44.0	176	50.9	131	39.6	95	39.3	58	36.5
Ceftriaxone Decreased Susceptibility	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Cefixime Decreased Susceptibility	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Azithromycin Decreased Susceptibility	5	1.4	18	5.2	16	4.8	28	11.6	26	16.4
Ciprofloxacin Decreased Susceptibility	13	3.6	2	0.6	4	1.2	2	0.8	2	1.3
Ciprofloxacin-Resistant	116	31.9	102	29.5	136	41.1	101	41.7	70	44.0
Other Drug Resistance*	159	43.7	111	32.1	121	36.6	86	35.5	59	37.1

¹ Minimum inhibitory concentration (MIC) ≥ 0.5 µg/mL

² MIC ≥ 0.5 µg/mL

³ MIC ≥ 2.0 µg/mL

⁴ MIC 0.125 to 0.50 µg/mL

⁵ MIC ≥ 1.0 µg/mL

* Other Drug Resistance includes penicillin and tetracycline.

Note: Totalling the types of resistance may add to more than total specimens, due to multi-drug-resistant specimens.

Source: Centers for Disease Control and Prevention, Gonococcal Isolate Surveillance Project, Sexually Transmitted Diseases Clinic Sites

California Department of Public Health, STD Control Branch